

Mucopolysaccharidosis Type I (Hurler Syndrome) R&D Pipeline Analysis Report, H2-2018

<https://marketpublishers.com/r/M92E170F44CEN.html>

Date: August 2018

Pages: 50

Price: US\$ 2,200.00 (Single User License)

ID: M92E170F44CEN

Abstracts

Mucopolysaccharidosis Type I (Hurler Syndrome) Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline products.

The Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline guide presents complete overview of drugs currently being developed for Mucopolysaccharidosis Type I (Hurler Syndrome). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline candidate.

Research and Development progress along with latest news related to each of the Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline candidates is included.

Major companies participating in therapeutic development of Mucopolysaccharidosis Type I (Hurler Syndrome) are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Mucopolysaccharidosis Type I (Hurler Syndrome) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Mucopolysaccharidosis Type I (Hurler Syndrome) clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in MucopolysaccharidosisType I (Hurler Syndrome) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE REPORT INCLUDES

Panorama of MucopolysaccharidosisType I (Hurler Syndrome) pipeline markets including statistics on therapeutic drugs and companies involved

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered

MucopolysaccharidosisType I (Hurler Syndrome) pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in MucopolysaccharidosisType I (Hurler Syndrome) pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with MucopolysaccharidosisType I (Hurler Syndrome) pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire MucopolysaccharidosisType I (Hurler Syndrome) pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global MucopolysaccharidosisType I (Hurler Syndrome) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Please Note: The report will be delivered in 2 working days after purchase

Contents

I. KEY FINDINGS

1. Companies Investing in MucopolysaccharidosisType I (Hurler Syndrome) Pipeline include

Number of Companies with MucopolysaccharidosisType I (Hurler Syndrome) projects in pre clinical Development

Number of Companies with MucopolysaccharidosisType I (Hurler Syndrome) projects in Clinical Development

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Americas

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Europe

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Asia Pacific

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Rest of the World

2. Pipeline Candidates include

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Agents in pre clinical/Discovery stage of Development

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Agents in Clinical Development stage

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Therapeutic Compounds received special status

Mechanism of Action of most pipeline Drugs

Small molecules among the MucopolysaccharidosisType I (Hurler Syndrome) Pipeline agents

II. INSIGHTS INTO MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE

1. Disease Overview

Introduction to MucopolysaccharidosisType I (Hurler Syndrome)

Symptoms and Causes of MucopolysaccharidosisType I (Hurler Syndrome)

Treatment or Prevention Options for MucopolysaccharidosisType I (Hurler Syndrome)

Other Details

2. Phase wise Pipeline Compounds

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Pre Clinical/Discovery stage Drugs

MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Phase 1 stage Drugs
MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Phase 2 stage Drugs
MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Phase 3 stage Drugs
MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Pre Registration stage
Drugs

3. Company wise MucopolysaccharidosisType I (Hurler Syndrome) Pipeline
Compounds

4. MucopolysaccharidosisType I (Hurler Syndrome) Pipeline by Mechanism of Action

III. MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE COMPOUND DETAILS

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE COMPANY BRIEFS

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE MARKET

VI. APPENDIX

1. About Us

2. Research Methodology

3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability

I would like to order

Product name: MucopolysaccharidosisType I (Hurler Syndrome) R&D Pipeline Analysis Report, H2-2018

Product link: <https://marketpublishers.com/r/M92E170F44CEN.html>

Price: US\$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M92E170F44CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970